Isoprinosine in HIV Patients With Viral Load > 50 y < 200 Copies/mL

• Status: Active, not recruiting
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Virological failure is a complication of treatment in patients with HIV, and it can be as high as 42% to first line treatment or around 18% in second line treatment. The reasons behind this phenomenon are several, including adherence to treatment (self-patient) or those related to the drugs (kinetics, interactions) and the virus itself (resistance patterns). People living with HIV needs treatment for all their lives, another factor to facilitate virus resistance and poor adherence to treatment. For that reason, it is necessary to look for additional therapeutic options to minimize this problem, and the use of immunomodulatory drugs is an interesting topic now. Among those drugs, isoprinosine hs been reported not only improve the immune response, it also has the capability to inhibit the replication of RNA virus. Then, we propose an open label clinical trial to evaluate the effect of isoprinosine in HIV patients with a virological load between 50 and 200 copies/ml.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidad San Francisco de Quito
• Treatments: Inosine Pranobex

Criteria

Inclusion Criteria:

• Older than 18 years old.

• Patients with a viral load (RNA of VIH) between > 50 and < 200 copies/mL after 24 weeks of antiviral therapy or after scheme change.

• Informed consent signature

Exclusion Criteria:

• Younger than 18 years old.

• No virologic failure or RNA of VIH > 200 copies/mL.

• Presence of a serious opportunistic infection.

• Renal failure (including litiasis) or presence of gout.

• Pregnancy.